Today: 14 May 2026

WBD stock today: Warner Bros Discovery ends flat as Netflix-Paramount battle nears Jan. 21 deadline

WBD stock today: Warner Bros Discovery ends flat as Netflix-Paramount battle nears Jan. 21 deadline

Warner Bros Discovery shares closed at $28.79, about 4% below Paramount Skydance’s $30-per-share tender offer, as the board continues to back a rival cash-and-stock deal with Netflix valuing WBD at $27.75 per share. Paramount Skydance last week amended its bid to bolster financing but kept the price unchanged. Investors are watching for new merger filings and Tuesday’s Fed minutes ahead of the Jan. 21 tender deadline.
30 December 2025
···
Coca-Cola stock edges up as Wall Street slips in thin year-end trade

Coca-Cola stock edges up as Wall Street slips in thin year-end trade

Coca-Cola shares closed up 0.4% at $70.16 on Monday, outperforming a broader U.S. market decline in light holiday trading. Investors rotated into defensive consumer staples as tech stocks fell. Treasury yields eased, supporting dividend-heavy names like Coca-Cola. No new company news or filings were reported Monday; the next earnings report is expected in February.
30 December 2025
·
Western Digital stock slips as tech cools; Fed minutes and Jan. 22 earnings date loom

Western Digital stock slips as tech cools; Fed minutes and Jan. 22 earnings date loom

Western Digital shares fell 1% to $179.68 Monday, swinging between $176.70 and $184.77 in volatile year-end trading. The stock is up 303% in 2025, outpacing rival Seagate. Investors await Federal Reserve minutes Tuesday and Western Digital’s earnings on Jan. 22. Broader markets closed lower, with the S&P 500 down 0.35% and the Nasdaq off 0.50%.
30 December 2025
····
MongoDB stock slides on “MongoBleed” security update as agencies warn of active exploitation

MongoDB stock slides on “MongoBleed” security update as agencies warn of active exploitation

MongoDB shares fell 2.9% to $423.14 Monday after the company disclosed a server vulnerability known as “MongoBleed.” U.S. and Australian cyber agencies warned the flaw is being exploited and set a federal patch deadline for Jan. 19. The vulnerability, tracked as CVE-2025-14847, affects multiple server versions. Most cloud-software peers saw smaller declines.
30 December 2025
··
Marvell stock slips today as chips cool into year-end; MRVL traders eye Fed minutes and CES

Marvell stock slips today as chips cool into year-end; MRVL traders eye Fed minutes and CES

Marvell shares fell 0.6% to $85.76 as chip stocks traded mixed ahead of year-end. Nvidia and Broadcom slipped, while Intel rose after a filing showed Nvidia bought $5 billion in Intel shares. The Dow lost 0.51%, S&P 500 dropped 0.35%, and Nasdaq fell 0.5%. Investors are watching Fed minutes, jobless claims, and Marvell’s upcoming CES CEO appearance.
30 December 2025
···
Oklo stock drops nearly 4% after co-founders shift 15 million OKLO shares into trusts

Oklo stock drops nearly 4% after co-founders shift 15 million OKLO shares into trusts

Oklo shares fell 3.7% to $74.09 Monday after SEC filings showed CEO Jacob DeWitte and COO Caroline Cochran transferred about 15.4 million shares, worth $1.1 billion, into family and annuity trusts at no cost. The stock slipped another 1% after hours. Trading volume reached 8.4 million shares. Broader markets closed lower ahead of key U.S. economic data and Fed minutes.
30 December 2025
·
Reddit stock jumps as Needham flags AI-search tailwind — here’s what’s next for RDDT

Reddit stock jumps as Needham flags AI-search tailwind — here’s what’s next for RDDT

Reddit shares rose 4% to $234.65 late Monday after opening at $225 and trading as high as $235.95. CTO Christopher Slowe disclosed sales of Class A shares under a preset plan after the bell. The gains came as investors weighed Reddit’s role as a cited source in AI-generated search results. The stock remains below its September peak despite a sharp rally since its March 2024 IPO.
30 December 2025
··
JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

JNJ stock today: J&J closes $3.05B Halda cancer deal, flags EPS hit — what’s next

Johnson & Johnson closed its $3.05 billion cash acquisition of Halda Therapeutics, a cancer drug developer, on Monday. The company said it expects about $0.20 in adjusted EPS dilution, split between the fourth quarter and 2026. JNJ shares ended down 0.02% at $207.56. Investors await the Jan. 21 earnings call for 2026 guidance.
30 December 2025
····
Disney stock ends higher as late SEC filing flags exec sale heading into final 2025 sessions

Disney stock ends higher as late SEC filing flags exec sale heading into final 2025 sessions

Disney shares rose 0.55% to $114.19 Monday, bucking declines in major U.S. indexes. A late SEC filing showed Sonia L. Coleman, Disney’s chief people officer, sold 2,431 shares for about $277,000 under a pre-arranged plan after a holiday delay in EDGAR access. Trading volume was below average ahead of year-end. Investors await Disney’s January dividend and new U.S. economic data Tuesday.
30 December 2025
··
IBM stock price today: shares inch up into year-end as investors eye Fed minutes and IBM earnings

IBM stock price today: shares inch up into year-end as investors eye Fed minutes and IBM earnings

IBM shares rose 0.2% to $305.71 on Monday, outperforming a broader market drop as the S&P 500 fell 0.3%. The move came amid thin year-end trading and news of former CEO Louis Gerstner’s death at 83. Investors now await Fed meeting minutes and jobless claims later this week. No major IBM-specific announcements were reported during the session.
30 December 2025
··
Chevron stock today: CVX closes higher as oil jumps and $120 million Frontera deal hits tape

Chevron stock today: CVX closes higher as oil jumps and $120 million Frontera deal hits tape

Chevron shares closed up 0.7% at $150.99 as oil prices climbed more than 2% on supply concerns tied to Ukraine and Yemen. Frontera Energy announced a two-year crude prepayment deal worth up to $120 million with a Chevron unit. Kazakhstan’s oil output dropped 6% in December, led by a 10% fall at the Chevron-led Tengiz field after export disruptions. U.S. crude inventories rose by 405,000 barrels last week.
30 December 2025
····
1 … 971 972 973 974 975 … 1,935

Stock Market Today

  • Ecovyst Earnings Show Potential Despite Weak Recent Results
    May 14, 2026, 4:15 PM EDT. Ecovyst Inc. (NYSE:ECVT) reported weak recent earnings, dampening immediate market response. However, a $16 million unusual expense, one-off in nature, obscures the company's underlying profit potential. Analysts expect improved profitability if these one-time costs do not recur. Though earnings per share (EPS) declined over the past year, the company's earnings potential remains promising. Investors should note Ecovyst faces three warning signs, highlighting risks to consider before investing. Overall, the outlook for Ecovyst's profits appears cautiously optimistic, with future quarters likely to reflect better results absent unusual charges.

Latest articles

Dow Jones Today: Dow Closes Back Above 50,000 as Cisco’s AI Rally Reshapes the Market After the Bell

Dow Jones Today: Dow Closes Back Above 50,000 as Cisco’s AI Rally Reshapes the Market After the Bell

14 May 2026
NEW YORK, May 14, 2026, 4:01 PM EDT The Dow Jones Industrial Average closed back above 50,000 on Thursday, lifted by a sharp gain in Cisco and a broader technology rally that also pushed the S&P 500 and Nasdaq higher after the bell. The blue-chip index gained 329.85 points, or 0.66%, to 50,023.05, while the S&P 500 rose 0.64% to 7,492.33 and the Nasdaq Composite added 0.77% to 26,604.97. (Reuters) The move mattered because it put the Dow back over a closely watched level while investors were already chasing record highs in the S&P 500 and Nasdaq. It also showed
REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

REGENXBIO Stock Plunges as Duchenne Gene Therapy Win Runs Into Safety Questions

14 May 2026
REGENXBIO shares fell 37% to $6.31 after its Duchenne muscular dystrophy gene therapy, RGX-202, met the main goal in a late-stage trial. Investors reacted to two serious adverse events and uncertainty over FDA approval. The company reported 93% of patients showed microdystrophin expression at 12 weeks. REGENXBIO said it will seek accelerated approval and targets a 2027 launch.
Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

Digi Power X Stock Slides Before Earnings as $1.1 Billion AI Deal Faces First Test

14 May 2026
Digi Power X shares fell 14% to $7.28 in heavy trading Thursday ahead of its first-quarter results and operations update due May 15. Investors are focused on its $1.1 billion, 10-year AI data-center deal with Cerebras and a $19.6 million SubQ AI GPU rental contract launching Friday. The company also expanded its at-the-market share-sale program to $175 million.
Go toTop